Page 14 - Life Sciences Practice News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): AGMEGM 27.05.2021 / 07:00 Geneva, Switzerland, May 27, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today gives notice of the Annual General Meeting (AGM) of shareholders to be held on June 18, 2021. As a result of the exceptional circumstances due to the co...

GENEVA, SWITZERLAND / ACCESSWIRE / May 27, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil)

Curative cell and gene therapies and healthcare system disruption SHARES Introduction Significant scientific advances have created a rich clinical research pipeline, with innovative and potentially curative cell and gene therapies already available (eg, Kymriah ® for acute lymphoblastic leukaemia, Luxturna ® for inherited retinal disease and Zolgensma ® for spinal muscular atrophy). Over the next 10 years, more of these therapies are expected to enter the market for other disease areas and larger patient populations. Potentially curative cell and gene therapies represent a key shift in pat...

Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery. A prime example of the future potential of AI is in revolutionizing the way we diagnose, monitor, and treat multiple sclerosis (MS), thereby advancing our understanding of the disease course. Today, MS continues to be...

Overcoming Funding Challenges For Innovative Medtech In Germany: Learnings From The NUB Process By Eva Marchese, Lorenzo D’Angelo, Anthony Barron, and Oriol Viader-Llargués, CRA Germany is the leading medtech market in Europe, with a 22% market share. While funding for high-cost innovative medtech in Germany has evolved in recent years, there are still many challenges in securing reimbursement even as demand for these technologies surges. In a new analysis conducted by our Life Sciences Practice team at CRA, we explored how medtech companies should approach the reimbursement pathway for th...